In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and Opdivo (nivolumab) doubled the progression-free survival benefit compared to Opdivo alone, with a manageable safety profile, according to results of the phase II/III RELATIVITY-047 clinical trial reported by The University of Texas MD Anderson Cancer Center.
Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.
